ASCO 2021: Updates in Solid Tumors

ASCO 2021: Updates in Solid Tumors

Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women

An increase in endometrial cancer incidence among young adult women in the United States coincides with an increase in the prevalence of obesity in this population, according to researchers.

Cancer Therapy Advisor
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
Targeting LAG-3 and PD-1 With Relatlimab and Nivolumab: A New Option Under Study in Advanced Melanoma

A novel immunotherapeutic combination—this one targeting the LAG-3 and PD-1 immune checkpoints—delays time to disease progression significantly more than nivolumab alone.

The ASCO Post

Does Vitamin D Supplementation Improve Prognosis for Patients With Breast Cancer?

A research team has found that sufficient vitamin D levels at the time of diagnosis may be associated with improved outcomes among people with breast cancer.

The ASCO Post
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma

In a presentation of real-world data, Miron et al conclude that the choice of first-line platinum CT does not result in a significant difference in OS benefit among patients with advanced bladder..

The ASCO Post
Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021

Data suggest short-term treatment with vorasidenib and Tibsovo reduces tumor cell proliferation, alters epigenetic state, and promotes expression of genes associated with cellular differentiation.<

Addition of Immunotherapy to Standard of Care First-Line Regimen Delays Disease Progression in Advanced Nasopharyngeal Carcinoma

Adding toripalimab to first-line chemo significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma, according to new research being presented at the

Tislelizumab Met Primary Endpoint of OS in Pivotal Phase 3 Trial of Esophageal Cancer After Systemic Therapy

Novartis announced today results from the pivotal phase III RATIONALE 302 trial showing that tislelizumab improved OS vs chemo in patients with unresectable recurrent locally advanced or metastatic

AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy

A new finding reveals that AI-based tissue analysis can show better prognosis for immunotherapy as well as find more patients eligible for the treatment.

Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors

Intensity Therapeutics today announced data from its on-going Phase 1/2 clinical trial in refractory patients demonstrating efficacy and tolerability of INT230-6, either as monotherapy or in combin

As ASCO 2021 Spotlights Biomarkers, New InCrowd Data Shows 80% of US Oncologists Anticipate Broader Liquid Biomarkers Use, Despite Insurance Barriers

With oncology biomarker testing advances featuring prominently in this week’s American Society of Clinical Oncology (ASCO 2021) agenda, new data show that 80% of US oncologists surveyed think liqui

Experts Discourage Intensive Follow-Up of Patients Treated for Endometrial Cancer

According to findings presented at the virtual 2021 ASCO Annual Meeting, the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer should be discouraged.

Oncology Learning Network
With Strong Screening and Vaccination Guidelines, Cervical Cancer Rates Drop; Other HPV-Related Cancers Are on the Rise

ALEXANDRIA, Va. – In a review of the incidence and trends of the Human Papillomavirus- (HPV-) related cancers, a new study found that over the last 17 years, the incidence of cervical cancer has decreased annually by 1%, while the incidence of other HPV-related cancers continues to increase.

2021 ASCO Annual Meeting Preview: Connect With One of the Largest, Most Diverse Audiences in Oncology

Six case-based panel sessions will be presented at ASCO 2021, featuring expert faculty discussing timely and challenging real-world clinical scenarios. The scheduled broadcast of these sessions will be highly interactive, offering both Q&A and participant polling.

Top Research to Be Presented in 2021 ASCO Annual Meeting Press Program

ALEXANDRIA, Va. – Advances in the treatment of prostate, breast, lung, and renal cancers as well as screening, prevention, access to care, immunotherapy, and precision medicine will be highlighted in the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting’s official Press Program. Studies featured in the Press Program are among the more than 4,900 abstracts part of the Meeting.

Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting

Dracen Pharmaceuticals announced today that a poster presentation updating the ongoing phase 1/2a, FIH study of DRP-104 in adults with advanced solid tumors will be presented during the trial in pr

Addressing the Challenges in Care for Patients With Gynecologic Malignancies Across the Globe

Improving outcomes for women with gynecologic cancers worldwide will be the focus of the Education Session “Equality in Care for All Women: Addressing Disparities in Gynecologic Malignancies” durin

ASCO Daily News
Education Session Addresses Structural Racism and Social Inequities in Cancer Care

Researchers, policy makers, and concerned citizens have become progressively vocal regarding their role in eliminating these disparities, particularly in regard to those also related to cancer care

ASCO Daily News
Education Session Navigates Strategies in Finding the Right Dose, From Phase I Trials to Clinical Practice

This education session from the 2021 ASCO Annual Meeting will include presentations discussing how to find the right treatment dose, from phase I clinical trials to real-world prescribing.

ASCO Daily News
Ready or Not: Oncology Adapts to Telehealth

The Education Session will provide attendees examples of how telehealth methods of cancer care delivery can be done well, adapt to diverse populations, and benefit patients and their families.

ASCO Daily News
Education Session Teaches Strategies for Greater Diversity in Clinical Trial Populations

Diversity in clinical trials is important for a variety of reasons, explains Dr Martin Gutierrez of John Theurer Cancer Center at Hackensack University Medical Center.

ASCO Daily News
With the Problem of Gender Diversity in Oncology Well Established, Education Session Focuses on Solutions

In 2017, for the first time, more women (50.7%) than men enrolled in residency programs across the US.

ASCO Daily News
Immunotherapy Delays Disease Recurrence in Patients With Early-Stage, Resected Non-Small Cell Lung Cancer

ALEXANDRIA, Va. – Treatment with the immunotherapy atezolizumab (Tecentriq) extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings open the door to delaying recurrence even longer for patients with early-stage disease.


source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)